MITOCHONDRIAL ENCEPHALOPATHY, LACTIC ACIDOSIS AND STROKE-LIKE EPISODES (MELAS SYNDROME)
Clinical trials for MITOCHONDRIAL ENCEPHALOPATHY, LACTIC ACIDOSIS AND STROKE-LIKE EPISODES (MELAS SYNDROME) explained in plain language.
Never miss a new study
Get alerted when new MITOCHONDRIAL ENCEPHALOPATHY, LACTIC ACIDOSIS AND STROKE-LIKE EPISODES (MELAS SYNDROME) trials appear
Sign up with your email to follow new studies for MITOCHONDRIAL ENCEPHALOPATHY, LACTIC ACIDOSIS AND STROKE-LIKE EPISODES (MELAS SYNDROME), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for MELAS: experimental drug tested for Long-Term safety
Disease control ENROLLING_BY_INVITATIONThis study is testing the long-term safety of a daily oral drug called zagociguat in 44 adults with MELAS, a rare genetic disease that affects energy production in cells. All participants previously completed a lead-in study of the same drug. Researchers will monitor side effects…
Matched conditions: MITOCHONDRIAL ENCEPHALOPATHY, LACTIC ACIDOSIS AND STROKE-LIKE EPISODES (MELAS SYNDROME)
Phase: PHASE2 • Sponsor: Tisento Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New pill aims to ease fatigue and brain fog in rare mitochondrial disease
Disease control OngoingThis Phase 2b trial tests an oral drug called zagociguat in 43 adults with MELAS syndrome, a rare genetic disorder that causes fatigue, muscle weakness, and stroke-like episodes. Participants take either 15 mg, 30 mg, or a placebo daily for 12 weeks. The study measures changes in…
Matched conditions: MITOCHONDRIAL ENCEPHALOPATHY, LACTIC ACIDOSIS AND STROKE-LIKE EPISODES (MELAS SYNDROME)
Phase: PHASE2 • Sponsor: Tisento Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC